View Full Text | Abstract |
Article as PDF | Print this Article |
Pubmed | PMC |
PubReader | Export to Citation |
Email Alerts | Open Access |
Exp Neurobiol 2017; 26(6): 350-361
Published online December 31, 2017
https://doi.org/10.5607/en.2017.26.6.350
© The Korean Society for Brain and Neural Sciences
Wuhyun Koh1,2, Yongmin Mason Park1,2, Seung Eun Lee3* and C. Justin Lee1,2,4*
1Division of Bio-Medical Science &Technology, Department of Neuroscience, KIST School, Korea University of Science and Technology, Seoul 02792, 2Center for Neuroscience and Functional Connectomics, Korea Institute of Science and Technology (KIST), Seoul 02792, 3Virus Facility, Research Animal Resource Center, Korea Institute of Science and Technology (KIST), Seoul 02792, 4Center for Glia-Neuron Interaction, Korea Institute of Science and Technology (KIST), Seoul 02792, Korea
Correspondence to: *To whom correspondence should be addressed.
C. Justin Lee, TEL: 82-2-958-6940, FAX: 82-2-958-6937
e-mail: cjl@kist.re.kr
Seung Eun Lee, TEL: 82-2-958-6959, FAX: 82-2-958-6937
e-mail: selee@kist.re.kr
Adeno-associated virus (AAV)-mediated gene delivery has been proposed to be an essential tool of gene therapy for various brain diseases. Among several cell types in the brain, astrocyte has become a promising therapeutic target for brain diseases, as more and more contribution of astrocytes in pathophysiology has been revealed. Until now, genetically targeting astrocytes has been possible by utilizing the
Keywords: Astrocytes, Dependovirus, Ventral Thalamic Nuclei, ALDH1L1 protein, human, Cre recombinase, Glial Fibrillary
Acidic Protein